These data raise the possibility that the novel non-intensive combination VEN + LDAC may be equivalent or superior to IC in terms of disease-free survival, treatment-related mortality and QoL for patients with NPM1 mutated AML who currently receive intensive therapy. This evidence concerns the gene NPM1 and acute myeloid leukemia.